Research in contextEvidence before this studyCutaneous T Cell Lymphomas are a heterogeneous group of which Mycosis Fungoides (MF) and Sèzary Syndrome (SS) are the most common subtypes; 5-year survival for advanced MF/SS is only 20%. Treatment for MF/SS is generally not curative; thus, selecting a therapy that is both effective and tolerable is critical to clinical decision-making. Histone deacetylase inhibitors (HDACi) have been used to treat CTCL for \>10 years, yet epigenome-wide histone acetylation, the direct target of these drugs, has not previously been mapped. Essentially all previously reported mechanisms of HDACi resistance were defined in cell lines, not in primary patient samples. Moreover, only \~30% of patients respond to HDACi, and we lack predictive markers for response.Added value of this studyOur study is the first to map epigenome-wide differences in chromatin acetylation (ChIP-seq) and link them to altered gene expression (RNA-seq) in HDACi-resistant CTCL (39 samples, 20 patients). We identified novel mechanisms of HDACi resistance in MF/SS patient samples and validated these findings in additional CTCL patient cohorts (RNA-seq, microarray). Elevated expression of several genes, including *BIRC5*, *NRP2*, and *LAIR2*, was detectable prior to HDACi therapy, suggesting their utility as predictive markers. Of these, LAIR2 was the most robust and is readily detected in patient plasma using routine clinical laboratory methods (ELISA).Implications of all the available evidenceOur study demonstrates that elevated levels of histone acetylation and novel cell adhesion/migration pathways are likely mechanisms of HDACi resistance in CTCL patients. While further studies are necessary, LAIR2 and other adhesion proteins may promote inflammation and migration of malignant and benign immune cells in the CTCL microenvironment. The predictive markers we identified represent novel therapeutic targets and could inform therapeutic decision-making in CTCL.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of non-Hodgkin lymphomas thought to derive from mature CD4+ skin-homing T lymphocytes \[[@bb0005]\]. Mycosis Fungoides (MF) and its leukemic variant, Sèzary Syndrome (SS), are the most common subtypes of CTCL. Patients with MF/SS have a highly variable clinical course. While some with early stage disease do not progress beyond limited skin disease and do not have significant morbidity or mortality from MF/SS, others develop advanced stage disease characterized by more extensive skin involvement, skin tumors, and lymph node and peripheral blood involvement. Those with advanced stage MF/SS have a 5-year overall survival of only 20% \[[@bb0010],[@bb0015]\]. Treatment for MF/SS is generally not curative, except for allogeneic stem cell transplant, which is a last resort. Therefore, selecting a therapy that is both effective and tolerable is a critical part of clinical decision making for treatment of MF/SS. Biologic agents, immunomodulators, targeted therapies, histone deacetylase inhibitors, and chemotherapy all have efficacy in some patients. However, except for CD30-targeted drugs, predictive biomarkers to guide choice of therapy do not exist for MF/SS \[[@bb0020]\].

Romidepsin and vorinostat, histone deacetylase inhibitors (HDACi), are two of the drugs FDA-approved for advanced MF/SS, underscoring the significance of histone modification in MF/SS pathogenesis and treatment. HDACs remove acetyl groups from lysine residues on histone proteins, causing condensation and decreased accessibility for transcription factors and other transcriptional machinery. HDACs also remove acetyl groups from non-histone proteins, including transcription factors. Thus, by broadly regulating transcription, HDACs modulate a wide range of cellular processes, including cell cycle and apoptosis, cell growth and survival, DNA repair, development and differentiation, each of which has been implicated in MF/SS pathogenesis when dysregulated \[[@bb0025], [@bb0030], [@bb0035], [@bb0040]\]. HDACi therefore may be effective in treating MF/SS because they disrupt many key cellular processes and may impact pathogenic pathways. However, the exact mechanism(s) of HDACi response and resistance remains largely unknown \[[@bb0030]\].

In the studies that led to the approval of romidepsin in MF/SS, the overall response rate on average was 34% with a median duration of response of 13·7--15 months \[[@bb0045],[@bb0050]\]. Nevertheless, clinical, biologic, or molecular markers that predict sensitivity or resistance to HDACi therapy in MF/SS have not been defined \[[@bb0005],[@bb0030]\]. Increases in bulk histone acetylation (measured by Western blot) have been reported with HDACi treatment of cell lines, primary normal cells, and primary MF/SS samples \[[@bb0055]\]. More recently, HDACi response in MF/SS was linked to global increases in accessible DNA and to enrichment in several transcription factor motifs as mapped by ATAC-seq. However, the differential ATAC-seq profiles could not be directly linked to changes in the gene expression because expression profiling was not performed in the same patient samples \[[@bb0060]\]. In other studies, genes and pathways have been associated with resistance to HDACi treatment, including ATP-binding cassette transporter, pro-apoptotic (Fas, Caspase), anti-apoptotic (BCL), JAK-STAT, MAPK/PI3K, NFKB, Redox, and TNF pathways \[[@bb0065],[@bb0070]\]. However, the majority of these studies were performed in cell lines and it is not clear that the same processes drive resistance in patients with MF/SS.

To address these outstanding questions, we performed chromatin immunoprecipitation and sequencing (ChIP-seq) and transcriptome sequencing (RNA-seq) on purified malignant T cells from skin biopsies and peripheral blood from patients treated with HDACi. Our studies revealed significant differences in the histone acetylation of gene regulatory elements in HDACi-resistant versus -sensitive samples and we linked these to significant expression changes in apoptosis, cell cycle, cytokine/chemokine signaling, and cell migration pathways. We identified a number of genes not previously associated with MF/SS or with HDACi-resistance. Notably, some of these changes are detectable prior to HDACi therapy. One of these novel HDACi-resistance genes, *LAIR2*, encodes a secreted collagen receptor protein that is also significantly elevated in the plasma of patients with HDACi-resistant MF/SS. In summary, we report the first epigenome-wide map of chromatin acetylation in primary MF/SS and link significant differences in acetylation to gene expression in HDACi-resistant versus -sensitive samples. Our findings identify previously unrecognized mechanisms of HDACi resistance and define novel predictive markers as potential targets for therapeutic development.

2. Materials and methods {#s0025}
========================

2.1. Sample collection {#s0030}
----------------------

De-identified peripheral blood draws or skin punch biopsies were obtained from patients seen at the Washington University School of Medicine Cutaneous Lymphoma Clinic under IRB-approved protocols with patients providing informed consent. Peripheral blood was also drawn from healthy volunteers at WUSM with IRB approval.

2.2. PBMC isolation from primary skin samples {#s0035}
---------------------------------------------

PBMCs were isolated from skin punches through mechanical separation and repeated flushing of the tissue with sort buffer (PBS, 1% FBS, 2 mM EDTA), followed by red blood cell lysis (155 mM NH~4~Cl, 10 mM KHCO~3~, 0.1 mM EDTA) for 10 min.

2.3. T cell isolation from peripheral blood samples {#s0040}
---------------------------------------------------

Primary peripheral blood samples were incubated with RosetteSep Human Monocyte (CD36) Depletion Cocktail for 15 min at room temperature, layered onto a Histopaque-1077 gradient, and centrifuged at 400*g* for 30 min with no brake. The interphase was collected and washed with 10 mL of sort buffer (PBS, 1% FBS, 2 mM EDTA), followed by red blood cell lysis (155 mM NH~4~Cl, 10 mM KHCO~3~, 0·1 mM EDTA) for 10 min. Cells were washed and resuspended in sort buffer. Malignant cell populations were isolated with the EasySep Human CD4 Positive Selection Kit according to the manufacturer\'s instructions or through FACS on a Sony iCyt Synergy SY3200 after staining with CD4 (Miltenyi Biotec Cat\# 130--092-373, RRID:AB_871684), CD7 (Miltenyi Biotec Cat\# 130--105-842, RRID:AB_2659107), and/or CD26 (Miltenyi Biotec Cat\# 130--093-441, RRID:AB_1103210) fluorophore conjugated antibodies.

2.4. Cell culture {#s0045}
-----------------

HH (ATCC Cat\# CRL-2105, RRID:CVCL_1280), HUT78 (ATCC Cat\# CRM-TIB-161, RRID:CVCL_0337), and Jurkat (ATCC Cat\# TIB-152, RRID:CVCL_0367) cell lines were acquired from ATCC. HH and Jurkat cells were cultured in RPMI (Gibco) media supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. HUT78 cells were cultured in IMDM (Gibco) media supplemented with 20% fetal bovine serum and 1% penicillin-streptomycin. Primary T cells were cultured in IMDM media supplemented with 20% fetal bovine serum and 1% penicillin-streptomycin. All cells were grown at 37 °C with 5% CO~2~. All cell lines were collected for RNA and gDNA extraction within 10 passages after receipt from ATCC.

2.5. In vitro *Romidepsin treatments* {#s0050}
-------------------------------------

Cells cultured as above were treated with 2·5 nM Romidepsin for 4 h, media was replaced, and cells were collected 20 h later for RNA-seq and ChIP-seq.

2.6. Luciferase reporter assays {#s0055}
-------------------------------

Putative regulatory regions were PCR amplified from HH, HUT78, or Jurkat cell line gDNA with Accuprime Pfx DNA polymerase (Invitrogen) using primers with a *Nhe*I or *Xho*I cut site added to their 5′ end ([Table S1](#ec0005){ref-type="supplementary-material"}). PCR samples were gel-extracted (Qiagen cat. 28,706), digested with NheI and XhoI (New England Biolabs), gel-purified again, and ligated into the Promega pGL4·23 plasmid overnight at 23 °C with T4 DNA ligase (New England BioLabs, cat. M0202S). Sanger sequencing confirmed successful cloning. 1 μg of each luciferase plasmid and 15 ng of Promega\'s pNL1·1·TK vector (\#N1501) were co-nucleofected into 1 × 10^6^ HUT78 cells with an Amaxa Nucleofector 2b system using the X-001 program and a homemade nucleofection buffer (SM1) as described \[[@bb0075]\]. Cells were incubated for 24 h in IMDM (Gibco) supplemented with 20% FBS and 1% penicillin-streptomycin, centrifuged at 200*g* for 10 min, and resuspended in 200 μL media. 60 μL were added to each well of a 96 well flat-bottom, white, opaque plate. The Promega Nano-Glo system (\#N1110) was used to read the firefly and renilla luciferase for each well according to the manufacturer\'s instructions in a BioTek Cytation5 platereader. All experiments were read in triplicate and performed at least twice. The average ratios between the firefly and renilla luciferase readings for each sample were compared to the average ratio for the empty pGL3-promoter vector to determine relative luciferase.

2.7. ChIP-seq {#s0060}
-------------

0.5--1.0 × 10^5^ cells were snap-frozen for 15 min on dry ice and stored at −80 °C until use. Ultra-low-input chromatin immunoprecipitation for H3K9/K14 ac (EMD-Millipore 06--599) and H3K27ac (Abcam ab4729) was performed as described \[[@bb0080]\]. DNA was sequenced by the Washington University Genome Technology Access Center on an Illumina Hi-Seq 3500 to generate 50 bp single-end reads. Reads were aligned to hg19 with bowtie2 (v2·2·5) with default settings \[[@bb0085]\]. Reads in ENCODE blacklisted regions were removed with samtools (v1·3) \[[@bb0090],[@bb0095]\]. Peaks were called with MACS2 (v2·1·0·20150420) with the settings --q 0·01 --m 10 50 ‐‐nomodel ‐‐shiftsize = 150 and input controls \[[@bb0100]\]. RPKM normalized genome browser tracks were created with deepTools\' (v3·1·0) bamCoverage utility with settings ‐‐binSize 10 ‐‐extendReads 150 ‐‐normalizeUsing RPKM and visualized on the UCSC genome browser \[[@bb0105],[@bb0110]\]. ChIPQC (v1·14·0) was used for quality control \[[@bb0115]\], and samples with fewer than 30% (H3ac) or 25% (H3K27ac) reads in peaks were removed from subsequent analyses. The DiffBind R package (v2·8·0) was used to derive consensus peak sets and determine differentially bound peaks between sample groups \[[@bb0120]\]. The chipSeeker R package (v1·16·1) was used to annotate peaks \[[@bb0125]\].

2.8. RNA-seq {#s0065}
------------

0·5-2 × 10^6^ cells from each sample were stored in 1 mL TRIzol reagent (Invitrogen cat. 15,596,026). RNA was isolated by the Washington University Tissue Procurement Center and sequenced by the Washington University Genome Technology Access Center on an Illumina Hi-Seq 3500 to generate 50 bp single-end reads. Reads were aligned to hg19 with UCSC annotations using STAR (v2·5·3a) \[[@bb0130]\]. RPKM normalized genome browser tracks were created with deepTools\' (v3·1·0) bamCoverage utility and visualized on the UCSC genome browser. Read quantification was performed by Salmon (v0·11·0) using UCSC hg19 knownGene annotations \[[@bb0135]\], and differential gene expression analyses were done with the DESeq2 R package (v1·20·0) \[[@bb0140]\]. Genotify (v1·2·1) was used for manual gene curation \[[@bb0145]\]. All data analysis was done in SoS Notebook environments \[[@bb0150]\]. All gene ontology and pathway enrichments were performed on the Enrichr web server \[[@bb0155]\].

2.9. Quantitative real-time PCR {#s0070}
-------------------------------

RNA was isolated from 0·5-2 × 10^6^ cells stored in 1 mL TRIzol reagent following reagent instructions. DNA was removed with the TURBO DNA-free kit (Invitrogen cat. AM1907) and cDNA synthesized from 1 μg of RNA with a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems cat. 4368814). PCR reactions were performed with SsoAdvanced Universal SYBR Green Supermix (Bio-Rad cat. 1725271) in a Bio-Rad CFX96 Connect. Target primers are available in [Table S1](#ec0005){ref-type="supplementary-material"}. Relative expression to healthy CD4+ cells was calculated via the ΔΔCT method \[[@bb0160]\].

2.10. LAIR2 ELISA {#s0075}
-----------------

Plasma was collected from primary MF/SS and healthy control peripheral whole blood by centrifuging for 15 min at 1500*g* within 30 min of collection in EDTA-coated tubes. Plasma was stored at −80 °C until use. The LAIR2 sandwich ELISA (LifeSpan Biosciences cat. LS-F6502) was performed according to manufacturer instructions with plasma samples diluted 1:2. All samples were read in duplicate, and a third-order polynomial regression line was fit to the standard curve to calculate concentration.

2.11. Statistical analyses {#s0080}
--------------------------

All statistical tests were performed with GraphPad Prism (v8·1·1).

2.12. Data accession {#s0085}
--------------------

Sequencing data was deposited in GEO: GSE132053. External datasets used include GEO: GSE59307, GSE9479, and GSE113113.

3. Results {#s0090}
==========

To define epigenetic changes that are associated with response or resistance to HDACi, we first sought to map the epigenome-wide histone acetylation landscape of primary patient CTCL samples. Patients being treated at the Cutaneous Lymphoma Clinic at the Washington University School of Medicine were consented for tissue banking. Patient demographics and clinical data are summarized in [Table 1](#t0005){ref-type="table"} and individual patient data is included in [Table S2](#ec0010){ref-type="supplementary-material"}. For this study, 20 patients had specimens collected and subjected to epigenome and transcriptome analyses. Comparisons of HDACi sensitivity or resistance were performed for 17 MF/SS patients treated with romidepsin (*n* = 14) or vorinostat (*n* = 3). Skin biopsies and peripheral blood were collected at timepoints prior to the start of HDACi therapy, during the course of therapy, and/or at subsequent follow-up visits. For romidepsin patients, "pre" specimens were collected just prior to first infusion and "post" specimens were collected at the end of the infusion, one week later (prior to the second infusion), or at subsequent visits ([Fig. 1](#f0005){ref-type="fig"}A and [Table S3](#ec0015){ref-type="supplementary-material"}). Thirty-nine specimens defined this "discovery set" for epigenome and/or transcriptome studies. We assigned these specimens to HDACi-sensitive or -resistant groups based on the patients\' clinical responses to HDACi therapy, determined by blinded review of the medical record. Sensitive: specimens from patients who experienced partial or complete responses or stable disease with HDACi therapy; Resistant: specimens from patients who experienced progressive disease during treatment with HDACi ([Tables 1](#t0005){ref-type="table"} and [Table S2](#ec0010){ref-type="supplementary-material"}, [Table S3](#ec0015){ref-type="supplementary-material"}). Assignment to these groups was based on HDACi response during the course of therapy in which the specimen was collected. We also collected peripheral blood from healthy volunteers and purified control CD4^+^ T cells. From patient specimens, we purified malignant MF/SS cells (CD4^+^/CD7^−^ or CD4^+^/CD26^−^, see Methods). Purity of malignant T cells from Resistant and Sensitive samples was similar (92.5% and \>99%, respectively); median purity for all samples was \>90%.

HDAC inhibitors prevent the deacetylation of chromatin histone proteins, resulting in increased levels of acetylation. Histone acetylation is most often an activating modification that leads to increased expression of nearby genes. Two of the most prominent of these are H3K9/14 ac (H3ac), which mark active enhancers and promoters, and H3K27ac, which marks active enhancers. Because cellular yields were limiting in primary MF/SS samples, we optimized a method for performing histone acetylation profiling (H3K27ac, H3K9/14 ac) from small numbers of cells: ultra-low input chromatin immunoprecipitation and sequencing (ULI-ChIP-seq) \[[@bb0165]\]. For comparison, we treated healthy control CD4^+^ T lymphocytes with romidepsin using a dose and timing based on existing literature and to mimic, to the extent possible, the exposure of primary MF/SS tumors treated in vivo \[[@bb0170]\]. RNA-sequencing of the same samples was performed in parallel.Fig. 1Epigenome-wide profiling identifies hyperacetylation of genes and regulatory elements in CTCL that responded or progressed on HDACi-therapy. a) Diagram of study design. b) Heatmap of differentially bound (FDR ≤ 0·05) H3ac peaks (*n* = 4868) Sensitive and Resistant groups. c) Violin plot showing differences in log2 fold changes for H3ac peaks enriched in Resistant samples categorized by functional genomic region (Kruskal-Wallis test; \*, *P* ≤ 0·05; \*\*, P ≤ 0·01; \*\*\*, P ≤ 0·001; \*\*\*\*, P ≤ 0·0001). d) Bar plot comparing RNA-seq log2 fold changes of genes associated with H3ac peaks enriched in Resistant samples (Incr.) to genes not associated with enriched peaks (Not Incr.). H3ac peaks are categorized by functional genomic region. (Mann-Whitney test; \*\*\*, *P* ≤ 0·001; \*\*\*\*, P ≤ 0·0001). Mean with 95% confidence interval shown.Fig. 1Table 1Summary of patient clinical characteristics.Table 1CharacteristicsWUSM cohort (*N* = 20)Age at diagnosis, median (range)65 (27--84)Sex: F, M %40%, 60%Ethnicity Caucasian %75% African-American %25%Deceased30%Initial Stage - rangeIA - IVA2Worst Stage - rangeIIA - IVA2IIA5%IIB20%IIIA5%IIIB10%IVA140%IVA215%N/A5%Treated with HDACi*N* = 17 Romidepsin82% Vorinostat18%HDACi sensitive/resistant Sensitive24% Resistant76%Previous therapy lines, n (%) 024% 118% 224% ≥ 335%

3.1. Altered acetylation corresponds to dysregulated gene expression in HDACi resistant MF/SS {#s0095}
---------------------------------------------------------------------------------------------

To define epigenetic and linked gene expression changes associated with HDACi resistance or response, we updated and optimized an integrative informatic pipeline that we had created previously to analyze ULI-ChIP- and RNA-seq data from serial MF/SS samples and the in vitro treated T cells (see Methods). Briefly, we used MACS2 to call acetylation peaks with an FDR q value \<0·01 \[[@bb0100]\]. We first derived consensus peak sets and then identified differentially bound peaks between sample groups using the DiffBind R package and an FDR q value \<0·05 \[[@bb0120]\]. The heatmap in [Fig. 1](#f0005){ref-type="fig"}B shows the \~5000 acetylation peaks with significantly altered activity in resistant compared to sensitive sample groups ([Table S3](#ec0015){ref-type="supplementary-material"}); the majority of these are increased in samples from patients with progressive disease on HDACi. Comparison of functional genomic regions (promoter, enhancer, exon, intron) revealed that the greatest number of significantly altered acetylation peaks are located within introns and distal intergenic regions (enhancers), compared to promoters and exons. Most of these peaks have increased acetylation in resistant samples (Fig. S1A). Indeed, we observed a greater than two-fold change (log2) in all functional genomic regions, with distal intergenic (enhancer) regions having the highest relative increase in acetylation ([Fig. 1](#f0005){ref-type="fig"}C). The small number of peaks with decreased acetylation in resistant samples similarly showed a greater than two-fold reduction in all functional regions (Fig. S1B). Because acetylation is an activating histone modification associated with increased transcription, we examined the expression of genes linked to genomic regions with significantly higher acetylation in resistant versus sensitive samples. As expected, genes with highly acetylated regulatory elements (distal enhancer regions and promoters), as well as exons and introns, had significantly higher expression compared to genes with unchanged or decreased acetylation at these elements ([Fig. 1](#f0005){ref-type="fig"}D). These data demonstrate that MF/SS tumors that progress during HDACi treatment have significantly increased histone acetylation at thousands of regulatory elements compared to HDACi-sensitive MF/SS tumors, and that their target genes exhibit significantly increased expression.

3.2. HDACi-resistant MF/SS exhibits high expression of anti-apoptotic, cell cycle, and cell adhesion/migration genes {#s0100}
--------------------------------------------------------------------------------------------------------------------

We next directly evaluated the transcriptomes of primary patient MF/SS samples based on their response to HDACi. Using DESeq2, we identified 491 genes with significantly different expression in resistant versus sensitive samples ([Fig. 2](#f0010){ref-type="fig"}A--B and [Table S3](#ec0015){ref-type="supplementary-material"}, [Table S4](#ec0020){ref-type="supplementary-material"}) \[[@bb0140]\]. Similar to the histone acetylation changes we observed above (see [Fig. 1](#f0005){ref-type="fig"}), a majority of significantly altered genes have higher expression in the HDACi-resistant group (357 up versus 134 down). To validate these expression changes in additional MF/SS samples, we obtained publicly available RNA-seq data from a study of early to advanced stage MF (*n* = 49) samples and healthy control CD4^+^ T cells (*n* = 3) \[[@bb0175]\]. Genes upregulated in HDACi-resistance also exhibited higher expression in MF samples compared to control CD4^+^ T cells from the Querfeld et al. study (Fig. S2A) \[[@bb0175]\]. In contrast, genes that were down-regulated in HDACi-resistant samples were not significantly different across this independent dataset (Fig. S2B).

Gene ontology and pathway analyses revealed several significantly enriched pathways for HDACi-resistance upregulated genes, but none for downregulated genes ([Fig. 2](#f0010){ref-type="fig"}C and [Table S5](#ec0025){ref-type="supplementary-material"}). A number of the upregulated genes in these pathways have been previously associated with MF/SS or HDACi treatment, but many are novel to this analysis of HDACi response/resistance in MF/SS. These include anti-apoptotic, *BCL2* (known) and *BIRC5* (novel); cell cycle, *CDK1* (known) and *CDC6* (novel); and proliferation, *RAB25* and *RBM11* (both novel) \[[@bb0180],[@bb0185]\]. We also observed a number of upregulated genes with inflammatory functions, such as *TNFAIP3*, which is known to be upregulated and/or mutated in B cell lymphoma \[[@bb0190], [@bb0195], [@bb0200], [@bb0205]\], and *STAT4*, which was reported to be downregulated in several MF/SS studies \[[@bb0210]\], but we find to be nearly two-fold upregulated (1·9 log2 fold change, *p* \< 0·0001) in HDACi-resistant samples. Quite striking was the number of extra-cellular matrix, cell adhesion, and cell migration genes that were upregulated in the resistant group, including several not previously associated with MF/SS: *CCR6* (known), *CCL28* (novel), *EPCAM* (novel), *VCAM1* (novel), and *LAIR2* (novel) \[[@bb0210], [@bb0215], [@bb0220], [@bb0225]\]. Upregulation of these genes in the resistant group suggest that increased proliferation, anti-apoptotic signaling, and higher levels of chemotaxis and migration may represent functional mechanisms of HDACi resistance and/or MF/SS progression.

Alterations in histone acetylation likely contribute to the differences in gene expression we identified in HDACi-resistant or responsive MF/SS. Indeed, upregulated genes had significantly higher levels of histone acetylation at regulatory elements and gene bodies compared to unchanged/downregulated genes, with promoters exhibiting the greatest relative increase in acetylation ([Fig. 2](#f0010){ref-type="fig"}D). Similarly, downregulated genes had significantly lower chromatin acetylation levels compared to genes with unchanged/increased expression, with promoters and exons exhibiting the greatest decreases in acetylation ([Fig. 2](#f0010){ref-type="fig"}E). Taken with the data presented in [Fig. 1](#f0005){ref-type="fig"}, these results further support a role for differential histone acetylation in HDACi resistance and link acetylation to anti-apoptotic, cell cycle, and cell adhesion/migration pathways as potential mechanisms of resistance and MF/SS progression.Fig. 2Genes in anti-apoptosis, cell cycle, cell adhesion and migration pathways are upregulated in Resistant samples. a) Heatmap showing mRNA expression of differentially expressed genes (adj. *p*-value ≤0·05) in Sensitive versus Resistant samples. Selected genes that are upregulated in Resistant samples are listed. b) Volcano plot of gene expression differences in Resistant versus Sensitive samples. DEGs (adj. p-value ≤0·05) are coloured orange. c) Select enriched (adj. p-value ≤0·05) Reactome terms for genes upregulated in Resistant samples (full list Table S4). d) Bar plot comparing log2 fold changes for H3ac peaks linked to genes with increased (Incr.) and unchanged/decreased (Not Incr.) expression in Resistant vs Sensitive samples. H3ac peaks are categorized by functional genomic region (Mann-Whitney test; \*\*\*\*, P ≤ 0·0001; mean with 95% confidence interval shown). e) Bar plot as in d, but for genes with decreased (Decr.) and unchanged/increased (Not Decr.) expression in Resistant vs Sensitive samples (Mann-Whitney test; \*\*\*\*, P ≤ 0·0001). Mean with 95% confidence interval shown.Fig. 2

3.3. *Primary MF/SS HDACi-resistance genes are distinct from those identified by* in vitro *studies* {#s0105}
----------------------------------------------------------------------------------------------------

A number of studies have identified mechanisms that contribute to HDACi resistance, the vast majority of which were performed in vitro, generally in cancer cell lines. Approximately 30 genes and proteins reportedly contribute to HDACi resistance, including those in ABC transporter (MDR), pro-apoptotic (Fas, Caspase), anti-apoptotic (BCL), heat shock, HDAC, JAK-STAT, MAPK/PI3K, NFKB, Redox, and TNF pathways \[[@bb0065],[@bb0070]\]. To evaluate these mechanisms in primary MF/SS samples, we examined the expression of genes in these pathways (*n* = 361) (Fig. S2C and [Table S6](#ec0030){ref-type="supplementary-material"}). Of these, 14 were significantly altered in resistant versus sensitive groups. Notably, only 3/14 had been previously associated with HDACi resistance: anti-apoptotic gene *BCL2* and PI3K genes *PIK3C2A* and *PIK3C2B*, and these latter two were significantly decreased in the resistant group while increases have been reported \[[@bb0065]\]. While other STATs were unchanged, we detected significantly increased expression of *STAT4*, which has not been previously connected to HDACi resistance. We also identified three genes involved in Redox pathways that had not previously been reported: *TXNDC5*, whose product catalyzes thiol-disulfide interchanges, and *GSTM1* and *GSTM3*, which are glutathione S-transferases that detoxify drugs, toxins, and reactive oxygen species. Decreases in TNF-related apoptotic pathway proteins are also associated with resistance to HDACi treatment in vitro \[[@bb0065]\], but we detected increases in two of these genes, *TNFRSF17* and *TNFAIP3*, both of which promote B cell survival, and no change in the rest of these genes (51/53). A caveat to this RNA-seq analysis is that it does not measure levels of protein or phosphoprotein, which may be different from mRNA levels. Nevertheless, we demonstrate that mRNA expression of most of the HDACi-resistance pathways previously identified in vitro are not significantly altered in primary MF/SS HDACi-resistant versus -sensitive groups. In addition, we identify *STAT4*, *TNFRSF17*, *TNFAIP3*, *GSTM1*, *GSTM3*, and *TXNDC5* as previously unrecognized genes whose upregulated expression may contribute to HDACi-resistance in MF/SS disease.

3.4. Differences in the expression of key resistance-associated genes are detectable pre-HDACi treatment {#s0110}
--------------------------------------------------------------------------------------------------------

We next asked which of the gene expression differences in MF/SS samples collected pre- and post-one-week romidepsin therapy coincided with, or diverged from, expression changes induced by in vitro romidepsin treatment of normal CD4^+^ T cells. We therefore compared RNA-seq from healthy donor CD4^+^ T cells pre- and post-romidepsin treatment and paired MF/SS samples collected immediately pre-infusion and one-week post-infusion of romidepsin. We identified genes with increased expression (log2 fold change ≥1) in paired post- versus pre-treatment MF/SS samples (\>2300) or healthy CD4+ T cells (800). Of these upregulated genes, only 136 were in common (5·8% of MF/SS, 17% of healthy CD4+ T cells) ([Fig. 3](#f0015){ref-type="fig"}A). The numbers of downregulated genes (log2 fold change ≤ −1) in each comparison were more similar: 1011 for MF/SS and 1154 for healthy CD4^+^ T cells. The 188 genes in common comprised 18·6% of MF/SS and 16·3% of healthy CD4+ T cell downregulated genes ([Fig. 3](#f0015){ref-type="fig"}B). As we observed with the MF/SS samples, genes with expression changes in HDACi-treated control T cells had corresponding changes in acetylation (Fig. S3). Thus, the MF/SS cells exhibited a substantially greater number of genes with increased expression after romidepsin treatment compared to healthy donor CD4^+^ T cells.Fig. 3Resistant-associated expression changes are detectable pre-HDACi treatment. a) Venn diagram showing overlap of genes upregulated (log2 fold change ≥1) by romidepsin treatment in paired MF/SS samples (one-week post-treatment vs immediately pre-treatment, purple) and genes upregulated in healthy CD4+ T cells (24 h post-treatment vs untreated, orange). b) Venn diagram showing overlap of genes downregulated (log2 fold change ≤ −1) by romidepsin treatment in paired MF/SS samples (as in A, purple) and genes downregulated in healthy CD4+ T (as in A, orange). c) Paired dot plots (left) and box plots (right) for select differentially expressed genes. Paired MF/SS pre-HDACi and one-week post-HDACi treatment samples connected (purple = Resistant, green = Sensitive). Paired healthy CD4+ T cell pre- and 24 h post-romidepsin treatment samples connected (orange). (Wald test -- DESeq2; \*\*, P ≤ 0·01; \*\*\*, P ≤ 0·001; \*\*\*\*, P ≤ 0·0001). Whiskers show 10-90th percentile. Pre = pre-HDACi treatment; Post = one-week post HDACi treatment; Untx = Untreated; Romi = Romidepsin treated; Rest = HDACi Resistant; Sens = HDACi Sensitive. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 3

Given that we observed significant differences in hundreds of genes in HDACi-resistant versus -sensitive groups ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}), we asked whether these differences were also detectable in the post- versus pre-treatment analysis. Indeed, we found that the HDACi-resistant MF/SS samples showed consistently higher expression of these differentially expression genes, and surprisingly, many of these were significantly increased in pre-treatment samples (Fig. S4). Several examples are shown in [Fig. 3](#f0015){ref-type="fig"}C. These include anti-apoptotic genes *BCL2* and *BIRC5* (Survivin), which promote proliferation and prevent apoptosis in multiple cancer types, including B and T cell lymphomas \[[@bb0230]\]. We also identified genes in cell cycle pathways such as *CDK1*, a cyclin-dependent kinase that promotes mitosis, and *RRM2*, a ribonucleotide reductase enzyme involved in DNA replication/repair. Cell adhesion pathway genes also showed this pattern in HDACi-resistance, including *NRP2*, whose protein product binds semaphorins and VEGF and is involved in the migration of T cells and other immune cells \[[@bb0235]\], and *LAIR2*, which codes for a secreted collagen receptor protein expressed by T and NK cells \[[@bb0240]\]. In an independent study of CTCL that did not evaluate HDACi therapy \[[@bb0175]\], expression levels of *RRM2*, *BIRC5*, *CDK1*, *CCR6*, *CXCR4*, and *LAIR2* are significantly higher in MF compared to control skin samples, with a trend toward higher expression in more advanced stages (Fig. S5). *NRP2* expression showed a non-significant trend toward higher expression in MF samples, but *BCL2* expression was not different from control skin (Fig. S5). The pattern of higher expression of these genes in advanced disease and HDACi-resistant samples, detectable pre- and post-HDACi, suggests that they may be involved in disease progression and/or mechanisms of HDACi resistance.

3.5. Highly acetylated regions demonstrate robust enhancer activity in reporter assays {#s0115}
--------------------------------------------------------------------------------------

To confirm enhancer activity of regions with higher levels of acetylation in HDACi-resistant versus sensitive samples, we performed luciferase reporter assays in an MF/SS cell line (HUT78) by adapting previously described protocols \[[@bb0245]\]. We selected putative enhancer regions that met the following criteria: 1) higher acetylation in resistant samples, 2) likely to regulate expression of nearby genes based on GeneHancer interactions and ENCODE transcription factor binding data, 3) target gene(s) with significantly elevated expression in resistant samples, and 4) the regulated genes have known or potential roles in lymphoma progression and/or drug resistance. Three gene loci with enhancer regions meeting these criteria were subjected to luciferase reporter assays ([Figs. 4](#f0020){ref-type="fig"} and S6). *CCR6* is a beta chemokine receptor expressed by normal memory T cells and MF/SS that may regulate their migration and recruitment in inflammation and MF/SS metastasis \[[@bb0215]\]. Expression of *CCR6* is significantly higher in resistant samples (Fig. S7), and the gene locus contains two distal intergenic elements upstream of the promoter/transcription start site (TSS) and two elements within the first intron that exhibit significantly higher levels of H3K27 and K3K9/14 acetylation in the resistant group ([Figs. 4](#f0020){ref-type="fig"}A and S6C). Luciferase assays confirmed strong enhancer activity in one of the intronic elements (6-fold higher activity compared to empty vector, [Fig. 4](#f0020){ref-type="fig"}B). In the *LAIR2* locus, we tested three regions with higher acetylation in resistant samples, two distal intergenic elements upstream of the promoter/TSS and another element in the second intron of *LAIR2* ([Figs. 4](#f0020){ref-type="fig"}C and S6D). Luciferase assays confirmed strong enhancer activity for the intronic element, with \>10-fold greater activitya compared to the vector alone ([Fig. 4](#f0020){ref-type="fig"}D). The chemokine receptor CXCR4 binds CXCL12/SDF-1 and this signaling axis plays major roles in cell migration and immune response \[[@bb0250]\]. *CXCR4* expression is higher in the resistant group (Fig. S7), and we identified three upstream intergenic regions with higher acetylation in resistant samples ([Figs. 4](#f0020){ref-type="fig"}E and S6E). Luciferase reporter assays demonstrated robust enhancer activity (\>5-fold) for the two most distal of these elements ([Fig. 4](#f0020){ref-type="fig"}F). These results demonstrate that highly acetylated elements near upregulated genes in resistant samples harbor strong enhancer activity, suggesting that these elements may drive high expression of genes that promote HDACi resistance in MF/SS.Fig. 4Luciferase reporter assays confirm enhancer activity for regulatory elements near HDACi-resistant upregulated genes. a) UCSC genome browser snapshot showing the CCR6 locus with representative Resistant and Sensitive samples. All signal tracks are normalized to reads per kilobase per million mapped reads (RPKM). Putative enhancer regions assayed by luciferase reporter are highlighted. b) Enhancer activity of putative CCR6 enhancer regions measured by luciferase reporter in HUT78 cells. All assays were performed at least twice and read in triplicate. Ratios are relative to empty vector. c) UCSC genome browser snapshot showing the LAIR2 locus with representative Resistant and Sensitive samples, as in a. d) Enhancer activity of putative LAIR2 enhancer regions (c) in HUT78 cells, performed as in b. e) Enhancer activity of putative CXCR4 enhancer regions (f) in HUT78 cells, performed as in b. (Mann-Whitney test \*, *p* ≤ 0·05; \*\*, p ≤ 0·01) Mean with standard deviation shown.Fig. 4

3.6. LAIR2 is a novel marker of HDACi-resistance in MF/SS {#s0120}
---------------------------------------------------------

Among the genes with highly acetylated enhancers and significantly upregulated expression in the HDACi-resistant group, *LAIR2* was particularly intriguing because of the degree of upregulation and its roles in T cell adhesion, migration, and activation \[[@bb0240],[@bb0255]\]. We confirmed the RNA-seq results using qRT-PCR for *LAIR2* in additional MF/SS samples from the same patients, including additional time points; in some cases, the additional samples were collected during treatment with non-HDACi therapies due to progression on HDACi. We also tested peripheral blood CD4^+^ T cells from healthy donors and T cell lines (Jurkat, leukemia; HH and HUT78, MF/SS). We found substantially higher levels of *LAIR2* mRNA in samples from patients with MF/SS that were progressing on HDACi therapy compared to normal CD4^+^ T cells or to samples from patients with MF/SS that was responding to therapy ([Fig. 5](#f0025){ref-type="fig"}A). We noted that in two samples from two patients with mixed response to therapy (i.e., response in lymph nodes/blood and progression in skin, 1126 B, 999), *LAIR2* expression was trending higher than samples from the same patient at different time points in complete response or compared to samples from other patients in complete response. *LAIR1* is a highly homologous gene located near *LAIR2* on chromosome 19q13·42. In contrast to *LAIR2*, *LAIR1* expression was not significantly higher in MF/SS compared to healthy control CD4^+^ T cells, and HDACi-resistant samples were not different from -sensitive ([Fig. 5](#f0025){ref-type="fig"}B).Fig. 5*LAIR2* is upregulated in multiple independent MF/SS datasets. a) *LAIR2* mRNA expression measured by qRT-PCR in healthy control CD4+ T cells, T cell lines, and primary MF/SS samples. Green bars: responding to therapy, Pink bars: mixed response to therapy; Purple bars: progressive disease. (Unpaired student\'s *t*-test compared to control; \*, P ≤ 0·05; \*\*, P ≤ 0·01; \*\*\*, P ≤ 0·001). Mean with standard deviation shown. b) *LAIR1* mRNA expression measured as in A. (Unpaired student\'s t-test compared to control; \*, P ≤ 0·05; \*\*, P ≤ 0·01; \*\*\*, P ≤ 0·001; \*\*\*, P ≤ 0·0001). Mean with standard deviation shown. c) *LAIR2* mRNA expression in CD4+ T cells purified from Sensitive and Resistant MF/SS samples (WUSM, RNAseq). d) *LAIR2* mRNA expression in control skin (*n* = 8) and primary MF (*n* = 6) (microarray; Mann-Whitney test; Humme et al., 2015). e) *LAIR2* mRNA expression in control skin (*n* = 3) and primary MF (*n* = 49) biopsies (RNAseq; Kruskall-Wallis test; Querfeld et al., 2018). c-e show mean with 95% CI. f) Diagram showing protein domains in LAIR2 and LAIR1. g) LAIR2 protein expression measured by ELISA in plasma from healthy controls and CTCL patients (colours as in A&B; unpaired Welch\'s t-test; \*\*, P ≤ 0·01). Mean with standard deviation shown. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 5

To evaluate *LAIR2* expression in additional MF/SS patient cohorts, we obtained publicly available expression data from four studies in which mRNA was collected from MF or SS samples and from healthy control CD4^+^ T cells in 2 of 4 studies \[[@bb0175],[@bb0260], [@bb0265], [@bb0270]\]. Similar to our findings in HDACi-resistant MF/SS samples measured by RNA-seq ([Fig. 5](#f0025){ref-type="fig"}C), *LAIR2* expression quantified by microarray was higher in MF and SS samples compared to control CD4^+^ T cells, ([Figs. 5](#f0025){ref-type="fig"}D and S8A) \[[@bb0265]\]. In a larger study using RNA-seq (49 MF, 3 control), *LAIR2* expression was significantly higher (two-fold on a log2 scale) in all stages of MF compared to controls \[[@bb0175]\]. More advanced stage disease (IIA and above) showed higher LAIR2 levels than early stage MF (IA/IB) in this study, as well as another CTCL study that performed microarray analysis ([Figs. 5](#f0025){ref-type="fig"}E and S8B) \[[@bb0260]\]. *LAIR1* levels were not statistically different in purified MF/SS cells from resistant versus sensitive samples (Fig. S8C) or were slightly decreased in Sezary cells (Fig. S8D) compared to healthy control CD4+ T cells \[[@bb0270]\]. In unsorted MF samples, *LAIR1* expression was increased relative to control samples (Fig. S8E) \[[@bb0175]\]. However unlike *LAIR2*, which is expressed only in T and NK cells, *LAIR1* is expressed on nearly all immune cells, including monocytes, macrophages, T, B, and NK cells, dendritic cells, mast cells, and eosinophils, so the increased levels may reflect the inflammatory microenvironment of MF-involved skin \[[@bb0275]\]. Thus, we demonstrate using several different methods that *LAIR2* expression is significantly higher in HDACi-resistant MF/SS disease.

The gene that encodes LAIR2 lies within the leukocyte receptor complex (LRC), a gene cluster on chromosome 19q13.4 that is rich in leukocyte immunoglobulin-like receptor (LIR) and Killer cell immunoglobulin-like receptors (KIRs) genes (Fig. S9). These genes encode transmembrane inhibitory and activating receptors expressed by T cells and/or NK cells, which are highly polymorphic; expression differences and genomic polymorphisms have been associated with auto-immune and infectious diseases \[[@bb0280],[@bb0285]\]. *LAIR2* is present in primates but absent in most other organisms, including mice (Fig. S9) \[[@bb0240]\]. In amino acid sequence, LAIR2 is highly homologous to the N-terminus of LAIR1, which includes the Ig-like domain, but lacks the transmembrane and intracellular domains that are present in LAIR1 ([Fig. 5](#f0025){ref-type="fig"}F). LAIR2 is a secreted protein and has been detected in the body fluids of patients with autoimmune disease \[[@bb0240],[@bb0290]\]. Therefore, we collected plasma from MF/SS patients and healthy donors and performed ELISA using an anti-LAIR2 antibody. Consistent with mRNA levels, we detected significantly higher levels of LAIR2 protein in MF/SS plasma compared to healthy controls ([Fig. 5](#f0025){ref-type="fig"}G). Notably, the patient with the lowest plasma concentration of LAIR2 protein, which was equivalent to healthy controls, has had a sustained response to romidepsin over four years of treatment (Patient 1125). Taken together, these results demonstrate that *LAIR2* mRNA and protein expression levels are significantly higher in both malignant cells and plasma from patients with HDACi-resistant MF/SS.

4. Discussion {#s0125}
=============

An outstanding question in CTCL research is why only a fraction of patients respond to HDACi therapy \[[@bb0030]\], and the related question of how response and resistance could be predicted to inform therapeutic choice. Here we have identified significant differences in the histone acetylation of gene regulatory elements in samples from CTCL patients with HDACI-resistant versus -sensitive disease and linked them to significant expression changes in cell cycle, apoptosis, cytokine/chemokine signaling, and cell adhesion/migration pathways. We and others have previously shown that high levels of acetylation of enhancers and promoters can lead to overexpression of oncogenes that promote cancer pathogenesis \[[@bb0245],[@bb0295], [@bb0300], [@bb0305], [@bb0310]\]. In this study, we demonstrated that enhancer elements near potential MF/SS oncogenes *CCR6*, *CXCR4*, and *LAIR2* had significantly increased acetylation levels in HDACI-resistant samples also showed strong enhancer activity by luciferase reporter assay. These results suggest that highly acetylated elements may drive the high expression levels of target genes in resistant samples, promoting enhanced chemotaxis, cell migration, and inflammation that contribute to progressive disease.

We validated our findings in several independent expression profiling studies of MF/SS, showing that HDACi-resistance genes were generally elevated in MF/SS compared to normal CD4+ T cells and several genes exhibited higher levels in more advanced stages of MF \[[@bb0175],[@bb0260], [@bb0265], [@bb0270]\]. One caveat is that these studies did not evaluate response to HDACi, however, there were no expression datasets with HDACi response data available for comparison to our study. Several HDACi-resistance genes had higher levels of acetylation and expression in pre-treatment samples, including *BCL2, CDK1, CXCR4* and *CCR6*. Previous studies have shown that knock-down or inhibition of BCL2, or deficiency of CDK1 family member, CDKN1A (p21), increased the sensitivity of cells treated with HDACi in vitro \[[@bb0315], [@bb0320], [@bb0325], [@bb0330], [@bb0335]\]. Other inhibition and knock-down studies demonstrated that CXCR4 and CCR6 may play a role in CTCL pathogenesis, though synergy with HDACi remains to be demonstrated \[[@bb0340], [@bb0345], [@bb0350], [@bb0355], [@bb0360]\]. We also identified several genes that had not been previously associated with MF/SS or HDACi-resistance, including *BIRC5*, *NRP2*, *RRM2*, and *LAIR2*, whose role in CTCL and HDACi-resistance may be further elucidated by future studies. Taken together, these results suggest that elevated levels of histone acetylation and novel cell adhesion/migration pathways are likely mechanisms of HDACi resistance in CTCL patients.

Our analysis of primary samples from HDACi-treated MF/SS patients also revealed several novel genes upregulated in previously identified HDACi resistance pathways. These include three genes in Redox pathways, *TXNDC5*, *GSTM1,* and *GSTM3,* which process therapeutic drugs and reactive oxygen species. Cells with altered levels of other components of these pathways have decreased cell death when treated with HDACi in vitro \[[@bb0065]\], and these three genes may contribute to in vivo mechanisms of HDACi resistance. *STAT4* expression was nearly two-fold in the resistant group, in contrast to previous reports of downregulation in Sèzary and upregulation in MF skin, though no association with HDACi resistance was previously reported \[[@bb0210]\]. Also, in contrast to published in vitro HDACi resistance studies, the resistant group exhibited higher expression of TNF pathway genes *TNFRSF17* and *TNFAIP3*, though notably both of these are associated with the pathogenesis of B cell lymphomas \[[@bb0190], [@bb0195], [@bb0200], [@bb0205],[@bb0365]\]. In summary, we identify *STAT4*, *TNFRSF17*, *TNFAIP3*, *GSTM1*, *GSTM3*, and *TXNDC5* as previously unrecognized genes whose upregulated expression may contribute to HDACi-resistance in primary MF/SS and may represent novel targets for therapeutic development.

One of the most striking differences we detected in HDACI-resistant compared to sensitive groups was elevated expression of *LAIR2*, a gene that encodes a secreted collagen receptor protein \[[@bb0240]\]. *LAIR2* mRNA was significantly higher in MF/SS skin biopsies and blood from patients with resistant disease, and the LAIR2 protein was elevated in the plasma of these patients. The *LAIR2* gene may have arisen by duplication from a close homologue, *LAIR1*, which encodes a transmembrane inhibitory receptor expressed on the majority of immune cells, in contrast to *LAIR2* expression only on T and NK cells \[[@bb0240]\]. The ligands of LAIR1 and LAIR2 receptors are collagen types I, III, and IV. When bound to collagens, LAIR1 transmits inhibitory signaling that reduces immune cell activation and proliferation ([Fig. 6](#f0030){ref-type="fig"}A) \[[@bb0255],[@bb0370]\]. Binding of collagen by LAIR2 prevents binding of LAIR1, which may promote activation, proliferation, and migration of malignant T cells from skin sites into lymph nodes and peripheral blood ([Fig. 6](#f0030){ref-type="fig"}B) \[[@bb0375],[@bb0380]\]. Downregulation of LAIR1-mediated inhibitory signaling may also contribute to inflammation in the MF/SS tumor microenvironment, in which benign immune cells are activated and contribute to morbidity of the disease \[[@bb0385]\]. In this way, MF/SS cells that produce LAIR2 might have a higher rate of proliferation and could more readily migrate through and out of tissue into lymphatics and/or the peripheral blood. LAIR2 could also promote a more inflammatory milieu by blocking collagen binding of LAIR1 on benign immune T and NK cells in the MF/SS microenvironment. Thus, LAIR2 represents a novel pathway for HDACi-resistance in MF/SS. It is also a potentially clinically useful marker for prognosis, HDACi resistance prediction, and monitoring disease burden and may represent a new therapeutic target for this challenging cancer.Fig. 6Proposed model for the role of LAIR2 in MF/SS pathogenesis. a) MF/SS cells that produce low/no LAIR2, such as in the Sensitive group, would still bind collagen through LAIR1, causing inhibitory signaling through LAIR1 ITIM domains. LAIR1-mediated inhibitory signaling could decrease proliferation, immune response, and inflammation. b) MF/SS cells that produce high levels of LAIR2, such as in the Resistant group, would have decreased binding of LAIR1 to collagen, causing decreased inhibitory ITIM signaling. Loss of LAIR1-inhibitory signaling could promote migration and proliferation of MF/SS cells and increased inflammation in the tumor microenvironment through decreased inhibitory signaling in local benign T and NK cells.Fig. 6

In conclusion, these studies are the first to connect differences in epigenome-wide acetylation and gene expression to HDACi resistance in primary samples from CTCL patients. Many of the HDACi resistance genes are involved in cell adhesion/migration, suggesting they may play a role in the variable manifestations of MF/SS disease in skin, lymph node, and peripheral blood. Elevated expression of several of these significantly altered genes was detectable prior to HDACi therapy, suggesting their utility as prognostic and/or predictive markers. Of these, we characterized LAIR2 as the most robust, which may contribute to inflammation and migration of MF/SS and benign immune cells in the microenvironment. Further studies to define the role of LAIR2 in MF/SS pathogenesis and progression, as well as its potential as a predictive marker and therapeutic target in this challenging cancer, are already underway.

The following are the supplementary data related to this article.Table S1Primers used for qRT-PCR and amplification of putative regulatory elements used in luciferase assays.Table S1Table S2Additional patient clinical information. Romi -- Romidepsin; Vori -- Vorinostat; Pre/Post-Treatment -- paired samples collected pre- and post-HDACi treatment.Table S2Table S3Sample groupings for ChIP-seq and RNA-seq analyses. Related to [Figs. 1](#f0005){ref-type="fig"}B and [2](#f0010){ref-type="fig"}B.Table S3Table S4Genes differentially expressed in resistant compared to sensitive samples and Romidepsin-treated versus untreated healthy CD4+ T cells.Table S4Table S5Gene pathway and ontology enrichment analyses for genes upregulated (adj. *p*-value ≤0·05) in resistant compared to sensitive samples.Table S5Table S6Genes in previously reported HDACi resistance pathways.Table S6Supplementary materialImage 1
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